Phenazone (antipyrone).
Phenazopyridine.
Phenindamine.
Pheniramine.
Phenylpropanolamine (norephedrine), preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when intended for the symptomatic relief of nasal and sinus congestion.
Phenytoloxamine.

Pholcodine,
a. oral solid preparations, in combination with one or more therapeutically active substances, and containing 20 milligrams or less of pholcodine (calculated as base) per dosage unit; (S6) or
b. liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, and containing 20 milligrams or less of pholcodine (calculated as base) per 5 milliliters dosage unit. (S6)

Pholedrine.
Pimethixene, preparations and mixtures thereof when used solely as an antihistaminic. (S5)
Pinaverium.
Pipenzolate.
Pipoxolan.
Pirbuterol, except when contained in respirator solutions. (S3)
Piroxicam,
a. when intended for the emergency treatment of acute gout attacks, and
b. when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S3)
Pizotifen; preparations and mixtures, when intended for prophylaxis of migraine. (S5)
Podophyllum resin; preparations and mixtures containing 20 percent or less thereof. (S4)
Poldine methylsulphate.
Polio vaccine.
Potassium chloride,
a. where the recommended dose is more than 20 millimol of potassium (1 500 milligrams of potassium chloride) per 24 hours, (S0)
b. except when intended for intravenous infusion or for injection; (S3) and
Schedule 2

c. except when contained in oral rehydration preparations. (S0)

Povidone iodine when intended for application to the vagina. (S0)

Prifinium bromide.

Procaterol, except when contained in respirator solutions. (S3)

Procyclidine.

Proglumide.

Proguanil, when used in combination with chloroquine and intended specifically for malaria prophylaxis. (S4)

Promethazine,

   a. when intended for use as an antihistamine, and
   b. when intended for application to the skin, and
   c. when intended specifically for the treatment of travel sickness. (S5)

Propantheline bromide.

Propyphenazone.

Proxymetacaine, when contained in eye drops intended for the emergency treatment of arc eyes. (S4)

Pseudoephedrine, contained in products registered in terms of the Act, and not intended for export,

   a. oral preparations and mixtures containing not more than 60 milligrams of pseudoephedrine per dose,
      and not more than 240 milligrams per day, when in combination with another pharmacologically active
      substance and intended for the symptomatic relief of colds and flu, subject to a maximum pack size of
      720 milligrams and limited to one pack per customer. (S6)

Pyrobutamine.

Quinine, preparations and mixtures containing not more than 1 percent thereof. (S4)

Ranitidine, when administered orally for short-term symptomatic relief of heartburn and hyperacidity, subject to -

   a. a maximum dose of 75 milligrams;
   b. a maximum daily dose of 300 milligrams;
   c. a maximum treatment period of two weeks. (S3)

Reproterol, except when contained in respirator solutions. (S3)

Rimiterol, except

   a. when contained in respirator solutions (S3) and
   b. when intended for injection. (S4)

Rubella vaccine.
Schedule 2

Sabadilla alkaloids; substances, preparations and mixtures containing 1 percent or more thereof.

Salbutamol, except
  a. when contained in respirator solutions; (S3) and
  b. when intended for injection. (S4)

Salmefamol, except
  a. when contained in respirator solutions; (S3) and
  b. when intended for injection. (S4)

Siccanin, when intended for application to the skin.

Sodium cromoglycate, except when intended for veterinary use. (S4)

Strychnine, preparations and mixtures containing 0.2 percent or less thereof. (S4)

Sulphadiazine silver when intended for application to the skin in the short-term treatment of minor burns, provided that the pack size is limited to a maximum of 50 grams. (S4)

Sulphonamides when intended for application to the eyes, nares and vagina; (S4)

Terbutaline, except when contained in respirator solutions. (S3)

Tetanus vaccine.

Tetracaine, when contained in eye drops intended for emergency treatment of arc eyes. (S4)

Tetrahydrozoline, except when intended for nasal use. (S1)

Thenalidine.

Thenyldiamine.

Theophylline and its derivatives, unless listed in another Schedule, and except in preparations for injection. (S4)

Thiethylperazine.

Tiaprofenic acid, when intended for the treatment of post-traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S3)

Timepidium.

Triamcinolone, when intended for application to oral lesions. (S4)

Trimebutine.

Trimeprazine (Alimemazine).

Tripelennamine.

Triprolidine.

Trospium.
Tulobuterol, except when contained in respirator solutions. (S3)

Typhoid vaccine.

Xylometazoline, except when intended for nasal use. (S1)

END SCHEDULE 2

SCHEDULE 3

a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –

(i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and

(ii) analytical laboratory purposes.

b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule include the following:

(i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

(ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Medicines Control Council, to patients under his/her care, the Schedule 3 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.

Acamprosate.

Acebutolol.

Aceclofenac.

Acetazolamide.

Acetohexamide.

Acetylcholine, when intended for ophthalmic use.

Acetylcysteine, when intended for injection. (S2)

Acipimox.
Schedule 3

Adapalene.

Adrenaline (epinephrine); ophthalmic preparations thereof, when intended for glaucoma. (S2, S4)

Alclofenac.

Alendronic acid.

Aliskiren.

Allopurinol.

Alpenolol.

Amiloride.

Amlodipine.

Ancrod.

Anthiolimine, when intended for injection.

Arsanilic acid.

Atenolol.

Atropine; ophthalmic preparations. (S2, S4)

Azapropazone.

Balsalazide.

Barnidipine.

Beclamide.

Benazepril.

Bendazac.

Benfluorex.

Benoxaprofen.

Benzbromarone.

Benzydamine, except preparations and mixtures containing -

a. 3 percent or less of benzydamine when intended for application to the skin (S1);

b. 0.15 percent or less of benzydamine when intended for use as a mouthrinse or for topical application in the mouth and throat: Provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day. (S1)

Bepridil.

Beta-benzalbutyramide.

Beta-galactosidase, when intended for therapeutic purposes.
Schedule 3

Betahistine.
Betaxolol.
Bethanidine.
Bevantolol.
Bezafibrate.
Bisoprolol.
Bopindolol.
Brimonidine.
Brinzolamide.

Bufexamac, except when intended for application to the skin. (S1)
Buflomedil.
Buformin.
Bumetanide.
Cadralazine.
Calcipotriol.
Calcium carbinimide.
Calcium salts, preparations thereof, when intended for injection, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).
Calcium disodium edetate, when intended for injection.
Calcium dobesilate.
Candesartan.
Captopril.
Carazolol.

Carbachol, ophthalmic preparations thereof when intended for glaucoma. (S4)
Carbamazepine.
Carbenoxolone, except when intended for application to the oral mucosa. (S0)
Carbuterol, when contained in respirator solutions. (S2, S4)
Carprofen.
Carteolol.
Carvedilol.
Celecoxib.
Celiprolol.
Chenodeoxycholic acid.
Chlorazanil.
Chlorexolone.
Chlorothiazide and other derivatives of benzo-1,2,4-thiadiazine-7-sulphonamide-1,1-dioxide, whether hydrogenated or not, including hydrochlorothiazide, bendrofluazide, benzthiazide, cyclopentiazide, hydroflumethiazide, metchlorothiazide and polythiazide.
Chlorpropamide.
Chlorthalidone.
Chromonar.
Ciclesonide
Cilazapril.
Cilomilast.

Cimetidine, except when intended for the short-term symptomatic relief of heartburn, dyspepsia and hyperacidity, subject to a maximum unit dose of 200 milligrams, a maximum daily dose (per 24 hours) of 800 milligrams and a maximum treatment period of 2 weeks. (S2)

Clofibrate.

Clonidine, except when intended for the treatment of migraine. (S2)

Clopidogrel.

Colchicine, except when intended for the emergency treatment of acute gout, subject to a maximum total treatment course of 6 milligrams. (S2)

Colestipol.

Copper salts, when intended for injection.

Corticosteroids (natural or synthetic), when contained in preparations intended for inhalation, except -

a. beclometasone dipropionate, when intended for nasal administration, other than by aerosol, indicated for the treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12, subject to a maximum dose per nostril of 100 micrograms, a maximum daily dose per nostril of 200 micrograms and a pack size limited to 200 doses; and

b. flunisolide, when intended for nasal administration, other than by aerosol, in a strength not exceeding 0,025 per cent (w/v), indicated for treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12, subject to, in the case of adults and children over the age of 16 years, a maximum dose per nostril is 50 micrograms and a maximum daily dose per nostril of 100 micrograms,
and in the case of children 12 to 16 years, a maximum dose per nostril of 25 micrograms and a maximum daily dose per nostril of 75 micrograms and a pack size limited to 240 doses; and

c. fluticasone propionate, when intended for nasal administration, other than by aerosol, in the short-term (less than 6 months) prophylaxis and treatment of symptoms of allergic rhinitis (hay fever) in adults and children over 12, subject to a maximum daily dose per nostril of 100 micrograms and a pack size limited to 120 doses. (S2, S4)

Cyclandalate.
Cyclopentolate, ophthalmic preparations thereof. (S2)

Darifenacin.
Debrisoquine.
Delapril.

Dialysate preparations.

Dichlorphenamide.

Diclofenac,
   a. except when intended for application to the skin; (S1) and
   b. except when intended for the emergency treatment of acute gout attacks; (S2) and
   c. except when intended for the treatment of post traumatic conditions, for a maximum treatment period of 5 days. (S2)

Diflunisal.
Diftalone.

Digitalis, its glycosides and other active principles thereof, unless diluted below one unit (BP) in each 2.0 grams.

Dihydroergocristine.

Dilevalol.

Diltiazem.

Dimercaprol, when intended for injection.

Dipivefrin.

Dipyridamole.

Dipyrocetyl.

Disulfiram.

Dithranol.

Dornase alfa (rh DNase).
Dorzolamide.
Doxazosin.
Eltenac.
Enalapril.
Endralazine.
Eprosartan.

Escin (aescin), except preparations and mixtures thereof intended for application to the skin and containing 1 percent or less of escin. (S1)

Esculin, when intended for oral use.

Esmolol.

Ethacrynic acid.

Ethambutol.

Ethionamide.

Ethosuximide.

Etisazol.

Etodolac.

Etodolic acid.

Etofenamate, except when intended for application to the skin. (S1)

Etoricoxib.

Exenatide

Felbamate.

Felbinac, except when intended for application to the skin. (S1)

Felodipine.

Fenbufen.

Fenclofenac.

Fendiline.

Fenofibrate.

Fenoprofen,

a. except when intended for the emergency treatment of acute gout attacks, (S2) and
Schedule 3

b. when intended for the treatment of post traumatic conditions, for a maximum treatment period of 5 days. (S2)

Fenoterol, when contained in respirator solutions. (S2, S4)

Fentiazac.

Fenticonazole, except when intended for application to the skin. (S1)

Firocoxib.

Floctafenine.

Flufenamic acid, except preparations and mixtures intended for application to the skin. (S1)

Fluorescein, except when intended for ophthalmic use by the topical route only. (S1)

Flunixin.

Flurbiprofen, except -

a. when intended for ophthalmic use; (S4)

b. when intended for application to the skin in adults and children 12 years and older only, including application by transdermal patch, subject to a maximum treatment period of 4 weeks; (S1)

c. when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S2)

d. in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to:

(i) a maximum treatment period of 3 days, and

(ii) a maximum of 8.75 milligrams per lozenge,

(iii) a maximum pack size of 15 lozenges (S1)

Fluticasone

Fosinopril.

Frusemide.

Gabapentin.

Gadoxetic acid.

Gemfibrozil.

Glafenine.

Glibenclamide.

Glibornuride.

Gliclazide.

Glimepiride.
Schedule 3

Glimidine.
Glipizide.
Gliquidone.

Glucosamine, substances, preparations and mixtures when intended for the treatment of primary and secondary osteoarthritis, osteochondrosis and spondylosis, except when registered as a feed supplement in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

Guanabenz.
Guanethidine.
Guanfacine.
Guanoxan.

Hexoprenaline, when contained in respirator solutions. (S2, S4)
Homatropine; ophthalmic preparations thereof. (S2)

Hormones (natural or synthetic, including recombinant forms), with either hormonal, prohormonal or antihormonal action, unless listed elsewhere in the schedules:

a. when intended for oral contraception;
b. except when intended for human vaginal use (S2), and
c. except hormones when specifically intended for emergency postcoital contraception. (S2, S4, S5)

Hydralazine.

Hydroquinone; preparations and mixtures thereof containing more than 2,0 percent hydroquinone. (S2)

Ibuprofen, except when used in oral medicinal preparations –

a. for the treatment of post-traumatic conditions for a maximum treatment period of 5 days, where the recommended daily dose for adults does not exceed 1,2 g and the dose for children up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2)
b. for the emergency treatment of acute gout attacks; (S2)
c. for the treatment of a haemodynamically significant patent ductus arteriosus in infants less than 34 weeks of gestational age. (S4)

Indapamide.

Indometacin, except

a. for application to the skin (S1), and
b. for the emergency treatment of acute gout attacks (S2).

Indoprofen.
Indoramin.

**Injections, unless listed in another Schedule.**

Insulin.

Ipratropium, except when contained in respirator solutions. (S2)

Irbesartan.


Isoniazid and its derivatives, unless listed in another Schedule.

Isoprenaline (isoproterenol), when contained in respirator solutions. (S2, S4)

Isosorbide.

Isoxicam.

Isradipine.

Ivermectin, except when intended and registered as an anthelmintic and/or ectoparasiticide in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

Ketanserin.

**Ketoprofen, except -**

a. when intended for application to the skin; (S1)

b. when intended for the short term management of headache, toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps (dysmenorrhea), minor aches and pains associated with the common cold and fever, subject to a maximum dose of 75 milligrams of ketoprofen in 24 hours; (S2)

c. when intended for the emergency treatment of acute gout attacks or for the treatment of post-traumatic conditions, subject to a maximum dose of 75 milligrams of ketoprofen per day and a maximum treatment period of 5 days. (S2)

Ketorolac trometamol, when intended for ophthalmic use. (S4)

Labetalol.

Lacidipine.

Lumiracoxib.

Lamotrigine.

Lercanidipine.

Levolthyroxine.
Levetiracetam.
Levobunolol.
Levosemindan.
Lidoflazine.
Lisinopril.
Lonazolac.
Lornoxicam.
Losartan.
Meclofenamic acid.
Mefenamic acid, except -
  a. when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; and
  b. preparations containing mefenamic acid as the only therapeutic active substance, when intended for the
     treatment of primary dysmenorrhea subject to a maximum daily dose of 500 milligrams mefenamic acid 3 times a day and a maximum treatment period of 3 days. (S2)
Meloxicam.
Mepindolol.
Mesalazine (5-aminosalicylic acid).
Mesulphene.
Metaproterenol (orcinrenaline), when contained in respirator solutions. (S2, S4)
Metformin.
Methazolamide.
Methimazole.
Methsuximide.
Methyldopa.
Metipranolol.
Metolazone.
Metoprolol.
Mibefradil.
Moexipril.
Montelukast.
Moxonidine.
Nabumetone, except when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S2)

Nadolol.

Naftidrofuryl.

Naproxen, except:

a. when intended for application to the skin; (S1)

b. the sodium salt, when intended for the short term management of headache, toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps (dysmenorrhoea), minor aches and pains associated with the common cold and fever, subject to a maximum dose of 600 milligrams naproxen (660 milligrams naproxen sodium) in 24 hours; (S2)

c. when intended for the emergency treatment of acute gout attacks; (S2)

d. when intended for the treatment of post traumatic conditions, for a maximum treatment period of 5 days. (S2)

Nateglinide.

Nebivolol.

Nicardipine.

Nifedipine.

Niflumic acid.

Nimesulide.

Nimodipine.

Nisoldipine.

Nitrendipine.

Nitroglycerine, when intended for medicinal use.

Normal Saline (Sodium chloride 0.9 % m/v) except for injection in a dosage form not exceeding 20 milliliters in volume. (S1)

Olsalazine.

Omesartan.

Orlistat.

Oxaprozin.

Oxcarbazepine.

Oxitocin.

Oxvinca.
Schedule 3

Oxyprenolol.
Oxybutynin.

Parecoxib.

Para-aminosalicylic acid and its esters.

Paracetamol, when intended for injection. (S0, S1, S2)

Parenteral Nutrition formulations.

Penbutolol.

Penicillinase, when intended for injection.

Pentaerythritol tetranitrate.

Pentolinium.

Pentosan polysulfate sodium, when intended for the treatment of interstitial cystitis. (S1)

Perindopril.

Phenformin.

Phenobarbital, preparations and mixtures containing not more than 90 milligrams of phenobarbital per minimum recommended or prescribed dose when intended for continued use in epilepsy. (S5)

Phenoxyphenylpenicillin, when intended for the prophylaxis of rheumatic fever. (S4)

Phentolamine.

Phenytoin.

Physostigmine; ophthalmic preparations thereof, when intended for glaucoma. (S4)

Pilocarpine; ophthalmic preparations thereof intended for glaucoma. (S4)

Pindolol.

Pioglitazone.

Piracetam.

Pirbuterol, when contained in respirator solutions. (S2)

Piretanide.

Piroxicam,

a. except when intended for the emergency treatment of acute gout attacks, (S2) or

b. when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S2)

Pirprofen.

Potassium canrenoate.
Potassium chloride, where the recommended dose is more than 20 millimol of potassium (1 500 milligrams of potassium chloride) per 24 hours (S2) or when intended for intravenous infusion or for injection, but except when contained in oral rehydration preparations, (S0)

Practolol.

Prazosin.

Primidone.

Probenecid.

Probucol.

Procaterol, when contained in respirator solutions. (S2)

Proctofene.

Propacetamol.

Propiverine.

Propranolol.

Proquazone.

Proscillaridine.

Prothionamide, when intended for oral use.

Pygeum africanum (lipido-sterolic complex extract thereof).

Pyrazinamide, when intended for oral use.

Pyrimethamine.

Pythioxin.

Quinapril.

Racecadotril.

Raloxifene.

Ramipril.

Ranitidine, except where administered orally for short-term symptomatic relief of heartburn and hyperacidity, subject to a maximum dose of 75 milligrams, a maximum daily dose of 300 milligrams and a maximum treatment period of two weeks. (S2)

Raubasine.

Rauwolfia alkaloids.

Repaglinide.

Reproterol, when contained in respirator solutions. (S2)
Reserpine (natural or synthetic).
Rimiterol, when contained in respirator solutions. (S2, S4)
Risedronate.
Rofecoxib.
Rosiglitazone.
Roxarzone (3-nitro-4-hydroxyphenylarsonic acid), when intended for veterinary use.
Salbutamol, when contained in respirator solutions. (S2, S4)
Salmefamol, when contained in respirator solutions. (S2, S4)
Solcoseryl; ophthalmic preparations thereof. (S0, S4)
Solifenacin.
Sotalol.
Spirapril.
Spironolactone.
Strophanthus; its glycosides and their hydrolysis products, and their derivatives, unless listed in another Schedule.
Sulindac.
Sulocitidil.
Sulphinpyrazone.
Sulthiame.
Suprofen.
Sylimarin.
Tasosartan.
Tazarotene.
Telmisartan.
Tenidap.
Tenoxicam.
Tepoxalin.
Terazosin.
Terbutaline, when contained in respirator solutions. (S2)
Terizidone.
Schedule 3

Terodiline.
Thiacetazone.
Thiocolchicoside.
Thyroid gland and its active principles and derivatives, unless listed in another Schedule.
Tiagabine.
Tiaprofenic acid, except when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S2)
Ticlopidine.
Timolol.
Tiotropium
Tolamolol.
Tolazamide.
Tolbutamide.
Tolfenamic acid.
Tolmetin, except when intended for application to the skin. (S1)
Tolterodine.
Topiramate.
Torasemide.
Trandolapril.
Tretinoin, when intended for application to the skin. (S5)
Triamterene.
Tricaine.
Trimethadione.
Tropicamide.
Tulobuterol, when contained in respirator solutions. (S2)
Ursodeoxycholic acid.
Valdecoxib.
Valproic acid and its derivatives, unless listed in another Schedule.
Valsartan.
Vedaprofen.
Schedule 3

Verapamil (iproveratril).
Veratrum alkaloids.
Vigabatrin.
Vincamine.
Vinpocetine.

Vitamin A; preparations thereof for injection and oral preparations and mixtures thereof containing more than 10 000 I.U. per recommended daily dose, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

Vitamin D; preparations thereof for injection and oral preparations and mixtures thereof containing more than 500 I.U. per recommended daily dose, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

Water for injection except in a dosage form not exceeding 20 milliliters in volume. (S1)

Xamoterol.
Xipamide.

Zafirlukast.

Zinc salts,

  a. for oral ingestion, where the daily dose is more than 50 milligrams of elemental zinc; (S0),

  b. except preparations thereof for injection, when intended for veterinary use; (S1) and

  c. except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

Zomepirac.

- END SCHEDULE 3 -

SCHEDULE 4

a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –

  (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and

  (ii) analytical laboratory purposes.
b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule include the following:

(i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

(ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Medicines Control Council, to patients under his/her care, the Schedule 4 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.

Abacavir.
Abatacept.
Acarbose.
Acediasulfone.

Acetarsone diethylamine salt, when intended for injection.

Acyclovir, except when intended for application to the lips in the early treatment of recurrent Herpes simplex virus infections. (S1)

Adalimumab.
Adenosine.

Adrenaline, when intended for injection. (S2, S3)

Aglipristone.

Alatrofloxacin.

Albendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

Alclometasone.

Alcuronium.

Aldesleukin.

Alefacept.

Alemtuzumab.

Alfuzosin.

Alizapride.